These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38777240)

  • 1. Improving the in vivo QTc assay: Nonclinical concentration-QTc modeling for risk assessment.
    Wisialowski TA; Ether N; Foley CM; Kleiman R; Koshman Y; Leishman D; Martel E; Nichols JV; Popp J; Rajamani S; Riley S; Rossman EI; Vargas HM
    J Pharmacol Toxicol Methods; 2024; 128():107515. PubMed ID: 38777240
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of ascending dose canine telemetry model supports its use in E14/S7B QT integrated risk assessments.
    Chaves AA; Ferraro JW; Yu J; Moye MJ; Yee KL; Li F; Steve DL; Lengel DJ; Regan CP
    J Pharmacol Toxicol Methods; 2024; 128():107525. PubMed ID: 38851600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14/S7B Q&As.
    Rossman EI; Wisialowski TA; Vargas HM; Valentin JP; Rolf MG; Roche BM; Riley S; Pugsley MK; Nichols J; Li D; Leishman DJ; Kleiman RB; Greiter-Wilke A; Gintant GA; Engwall MJ; Delaunois A; Authier S
    J Pharmacol Toxicol Methods; 2023; 123():107270. PubMed ID: 37164235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.
    Vargas HM; Rolf MG; Wisialowski TA; Achanzar W; Bahinski A; Bass A; Benson CT; Chaudhary KW; Couvreur N; Dota C; Engwall MJ; Michael Foley C; Gallacher D; Greiter-Wilke A; Guillon JM; Guth B; Himmel HM; Hegele-Hartung C; Ito M; Jenkinson S; Chiba K; Lagrutta A; Levesque P; Martel E; Okai Y; Peri R; Pointon A; Qu Y; Teisman A; Traebert M; Yoshinaga T; Gintant GA; Leishman DJ; Valentin JP
    Clin Pharmacol Ther; 2021 Feb; 109(2):310-318. PubMed ID: 32866317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the in Vivo QTc assay: The value of implementing best practices to support an integrated nonclinical-clinical QTc risk assessment and TQT substitute.
    Vargas HM; Rossman EI; Wisialowski TA; Nichols J; Pugsley MK; Roche B; Gintant GA; Greiter-Wilke A; Kleiman RB; Valentin JP; Leishman DJ
    J Pharmacol Toxicol Methods; 2023; 121():107265. PubMed ID: 36997076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from a Joined Prospective Study to Evaluate the Sensitivity of the In Vivo Dog QT Assay in Line with the ICH E14/S7B Q&A Best Practices.
    Bétat AM; Delaunois A; Delpy E; Loiseau M; Maurin A; Poizat G; Possémé C; Weinelt F; Drieu la Rochelle C; Martel E; Valentin JP
    Clin Pharmacol Ther; 2024 Jul; 116(1):106-116. PubMed ID: 38709223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of moxifloxacin in canine and non-human primate telemetry assays: Comparison of QTc interval prolongation by timepoint and concentration-QTc analysis.
    Chui RW; Baublits J; Chandra FA; Jones ZW; Engwall MJ; Vargas HM
    Clin Transl Sci; 2021 Nov; 14(6):2379-2390. PubMed ID: 34173339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simple accurate method for concentration-QTc analysis in preclinical animal models.
    Sadko KJ; Leishman DJ; Bailie MB; Lauver DA
    J Pharmacol Toxicol Methods; 2024; 128():107528. PubMed ID: 38852684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational Models and Tools to Reduce Clinical Trials and Improve Regulatory Decision Making for QTc and Proarrhythmia Risk (ICH E14/S7B Updates).
    Strauss DG; Wu WW; Li Z; Koerner J; Garnett C
    Clin Pharmacol Ther; 2021 Feb; 109(2):319-333. PubMed ID: 33332579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the sensitivity of cross-over and parallel study designs for QTc assessment: An analysis based on a single large study of moxifloxacin in 48 nonhuman primates.
    Leishman DJ; Holdsworth DL; Best DD; Roche BM
    J Pharmacol Toxicol Methods; 2023; 123():107299. PubMed ID: 37495163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular monkey telemetry: sensitivity to detect QT interval prolongation.
    Chaves AA; Keller WJ; O'Sullivan S; Williams MA; Fitzgerald LE; McPherson HE; Goykhman D; Ward PD; Hoe CM; Mixson L; Briscoe RJ
    J Pharmacol Toxicol Methods; 2006; 54(2):150-8. PubMed ID: 16679034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assay sensitivity in "Hybrid thorough QT/QTc (TQT)" study.
    Huang DP; Chen J; Dang Q; Tsong Y
    J Biopharm Stat; 2019; 29(2):378-384. PubMed ID: 30346877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499.
    Chaves AA; Zingaro GJ; Yordy MA; Bustard KA; O'Sullivan S; Galijatovic-Idrizbegovic A; Schuck H; Christian DB; Hoe CM; Briscoe RJ
    J Pharmacol Toxicol Methods; 2007; 56(2):103-14. PubMed ID: 17643323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in vivo QTc core assay: An evaluation of QTc variability, detection sensitivity and implications for the improvement of conscious dog and non-human primate telemetry studies.
    Baublits J; Vargas HM; Engwall MJ
    J Pharmacol Toxicol Methods; 2021; 109():107067. PubMed ID: 33857614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ICH S7B In Vitro Assays Do Not Address Mechanisms of QT
    Wu WW; Choe M; Johannesen L; Vicente J; Bende G; Stockbridge NL; Strauss DG; Garnett C
    Clin Pharmacol Ther; 2023 Dec; 114(6):1332-1341. PubMed ID: 37702218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin.
    Holzgrefe HH; Cavero I; Buchanan LV; Gill MW; Durham SK
    J Pharmacol Toxicol Methods; 2007; 55(3):227-37. PubMed ID: 17097307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scientific Review of the Proarrhythmic Risks of Oligonucleotide Therapeutics: Are Dedicated ICH S7B/E14 Studies Needed for Low-Risk Modalities?
    Qu Y; Henderson KA; Harper TA; Vargas HM
    Clin Pharmacol Ther; 2024 Jul; 116(1):96-105. PubMed ID: 38362953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of validity of standard nonclinical group size selection versus standard clinical group sizes for nonhuman primate QTc prolongation evaluation.
    Holdsworth D; Best DD; Haist K; O'Donohue K; Phillips A; Abernathy MM; Roche B; Leishman DJ
    J Pharmacol Toxicol Methods; 2023; 120():107253. PubMed ID: 36806737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of moxifloxacin and its concentration-QT interval relationship modeling in Chinese healthy volunteers.
    Xu FY; Huang JH; He YC; Liang LY; Li LJ; Yang J; Yin F; Xu L; Zheng QS; Wang K
    Acta Pharmacol Sin; 2017 Nov; 38(11):1580-1588. PubMed ID: 28713157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the performance of contemporary, historical, and cross-lab controls in QTc assessment in conscious nonhuman primates.
    Abernathy MM; Best DD; Leishman DJ
    J Pharmacol Toxicol Methods; 2024; 127():107510. PubMed ID: 38705245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.